-
Fintech Focus For August 19, 2020
Tuesday, August 18, 2020 - 5:39pm | 1972Read More...Quote Of The Day: Central bank independence? Gone. - Ben Melkman Fintech Movers: Despite all the talk surrounding digital transformation and the changes that coronavirus has spurred on, not all traditional banks have achieved full digital transformation. - Banking Dive Wealth Builders taps...
-
A Look At Teva's Paragard IUD Asset Sale To Cooper Companies, From Both Sides
Wednesday, September 13, 2017 - 9:14am | 590Read More...Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) said Tuesday it has agreed to sell its Paragard IUD product to Cooper Companies Inc (NYSE: COO) in a $1.1 billion cash deal. Teva also confirmed it will continue divesting the remaining assets it holds within the women's health portfolio along...
-
Teva's New CEO Is A Positive Catalyst
Monday, September 11, 2017 - 8:35am | 451Read More...Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) were trading higher by more than 11 percent early Monday morning after the company named Kare Schultz as its new CEO after a seven-month search period. Schultz brings decades of experience in the pharmaceutical industry and most...
-
Teva Downgraded As Analyst Casts Doubt On Turnaround Story
Thursday, August 3, 2017 - 1:19pm | 337Read More...Based on the nearly 25-percent decline in Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s stock price on Thursday, some investors and analysts have legitimate concerns over the company's earnings report and outlook. Among those on Wall Street who share this concern include...
-
Is Teva's 4% Dividend Yield Safe?
Tuesday, February 7, 2017 - 2:42pm | 329Read More...Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) plunged more than 5 percent after the company's CEO and President Erez Vigodman will step down, effective immediately. Yithak Peterburg, Teva's chairman since early 2015, will replace Vigodman at a time when the company is also...
-
Teva Pharmaceuticals Hit With A Slew Of Downgrades Following Guidance Revision
Wednesday, November 16, 2016 - 2:38pm | 698Read More...Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) hit a new 52-week low of $37.25 on Tuesday after the company reported its third-quarter results and provided a concerning outlook for the full year given some concerns over its specialty drugs. The stock rebounded slightly on Wednesday...
-
'Ugly Shoes' Still Hot On Social Media
Friday, June 10, 2016 - 10:21am | 312Read More...According to the latest data from TickerTags, the “ugly shoe” trend is alive and well. TickerTags monitors social media sites to identify trends by searching for words or phrases that appear together in social media content, such as tweets. Several major fashion articles in recent weeks...
-
Report: Teva Looking To Win Early EU Approval For Its Acquisition Of Allergan's Generics Unit
Wednesday, February 17, 2016 - 3:49pm | 201Read More...According to a report from Bloomberg, Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) is looking to win an early European Union approval for its $40.5 billion takeover of Allergan plc Ordinary Shares (NYSE: AGN)'s generics business. Reuters, citing "a person familiar with the...
-
Teva Shareholders Shrug Off Latest Collaborative Research Agreement
Tuesday, February 2, 2016 - 3:18pm | 298Read More...Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) announced on Tuesday it has entered into a new collaborative research agreement with AbCellera, a privately held company that has developed a high-throughput platform for the rapid discovery of therapeutic antibodies directly from natural immune...
-
Teva Pharmaceutical: Joint Venture With Takeda Will Be 'Instantly Accretive' To 2016 EPS And Beyond
Monday, December 28, 2015 - 10:55am | 211Read More...Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) established a joint business venture with Japan-based Takeda Pharmaceutical Company at the end of November. The companies updated the investment community on Sunday and offered details of their strategic partnership. According to a joint...
-
Teva Buys Allergan Unit: How Mylan, Other Biotech Stocks Are Reacting
Monday, July 27, 2015 - 12:08pm | 340Read More...Shares of Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) surged to new 52-week highs of $69.42 on Monday after the company announced its acquisition of Allergan PLC (NYSE: AGN)'s Generics segment for a total consideration of $40.5 billion. Shares of Allergan also spiked to new 52-...
-
Report: Mylan Could See Sweetened Bid From Teva Pharmaceutical
Wednesday, May 27, 2015 - 3:55pm | 262Read More...Teva Pharmaceutical Industries Ltd (NYSE: TEVA) will soon sweeten its $40 billion bid for Netherlands-based Mylan Inc (NASDAQ: MYL) and may resort to Dutch courts if the offer gets rejected, according to a report Wednesday. Mylan changed hands recently up about 1.7 percent at $71.72. Teva may...
-
What's Gabelli Saying About Teva Now?
Wednesday, April 22, 2015 - 11:51am | 319Read More...In a report published Wednesday, Gabelli & Company analyst Kevin Kedra commented on Teva Pharmaceutical Industries Ltd (NYSE: TEVA)'s offer to acquire Mylan NV (NASDAQ: MYL) for $82 per share. Teva argued that the acquisition could realize $2 billion of synergies, resulting in $10 billion...
-
And The Winner From The Mylan-Perrigo Merger Is... Teva?
Thursday, April 9, 2015 - 9:16am | 270Read More...In a report published Wednesday, Citigroup analyst Liav Abraham commented on a Mylan NV (NASDAQ: MYL) and Perrigo Company plc (NYSE: PRGO) combination, noting that a bid from Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) is still possible, but challenging. According to Abraham, if Teva is...
-
JPMorgan Says Mylan Has 3 Paths To Upside
Wednesday, April 8, 2015 - 11:04am | 420Read More...In a report published Wednesday, JPMorgan analyst Chris Schott shared his thoughts on Mylan NV (NASDAQ: MYL). According to Schott, Mylan shares are showing an "increasingly attractive" set-up with solid organic growth prospects (12 percent earnings per share compounded annual growth...
